Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK boosts board-level...

    GSK boosts board-level science as new CEO prepares to take over

    Written by supriya kashyap kashyap Published On 2016-12-22T11:13:12+05:30  |  Updated On 22 Dec 2016 11:13 AM IST
    GSK boosts board-level science as new CEO prepares to take over

    Drugmaker GlaxoSmithKline is bolstering scientific expertise on its board by establishing a new science committee, charged with overseeing research, as a new chief executive prepares to take over.


    Incoming CEO Emma Walmsley, the first woman to lead a top global drugmaker, stands out among Big Pharma bosses as a consumer brands specialist rather than a prescription medicines expert.


    Since her appointment in September she has spent much of her time learning about GSK's prescription drug research and development (R&D), according to company insiders. She takes over from Andrew Witty at the end of March.


    Britain's biggest drugmaker said that its new science committee would be chaired by non-executive director Jesse Goodman, a former chief scientist for the U.S. Food and Drug Administration.


    Patrick Vallance, president of R&D, will also join the GSK board as an executive director on Jan. 1, ahead of the retirement of current research head and board member Moncef Slaoui on March 31.


    Despite GSK's diversified structure, which includes vaccines and consumer health products, drug discovery remains a core activity and the company expects important clinical results for between 20 and 30 experimental medicines by the end of 2018.


    Walmsley herself has described R&D as "the beating heart" of the group.

    Andrew WittyBig PharmaEmma WalmsleyGlaxoSmithKlineGSKJesse GoodmanUS Food & Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok